NEW
Tecentriq特善奇

Tecentriq Indications/Uses

atezolizumab

Manufacturer:

Roche

Distributor:

DKSH
/
Agencia Lei Va Hong
Full Prescribing Info
Indications/Uses
840 mg/14 mL: Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): after prior platinum-containing chemotherapy; or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see Pharmacology: Pharmacodynamics under Actions).
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq (see Pharmacology: Pharmacodynamics under Actions).
Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
1,200 mg/20 mL: Urothelial carcinoma: Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): after prior platinum-containing chemotherapy; or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see Pharmacology: Pharmacodynamics under Actions).
Non-small cell lung cancer: Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see Pharmacology: Pharmacodynamics under Actions).
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq (see Pharmacology: Pharmacodynamics under Actions).
Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC (see Pharmacology: Pharmacodynamics under Actions).
Small cell lung cancer: Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see Pharmacology: Pharmacodynamics under Actions).
Hepatocellular carcinoma: Tecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see Pharmacology: Pharmacodynamics under Actions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in